ga naar hoofdinhoud
Informatie voor zorgverleners Behandelprotocollen Ziekte van Waldenström (WM) Richtlijnen en literatuur

Richtlijnen

Klik HIER voor de richtlijn 'Walden­ström's macroglobulinemie' van de HOVON Waldenström's macro­globulinemie werkgroep en HOVON Lymfoom werkgroep.

Literatuur

  1. Kastritis E et al. Waldenström’s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2018  (Supplement 0): iv1–iv10
  2. Treon SP et al. Genomic landscape of Waldenstrom macroglobulinemia and its impact on treatment strategies. J Clin Oncol. 2020; 38(11):1198-1208
  3. Dimopoulos MA, Kastritis E. How I treat Waldenström’s macroglobulinemia. Blood. September 2019
  4. Kastritis E et al. A revised international prognostic score system for Waldenstrom’s macroglobulinemia. Leukemia. 2019; 33(11):2654-2661
  5. Treon SP et al. Long-term follow-up of ibrutinib monotherapy in symptomatic, previously treated patients with Waldenström macroglobulinemia. J Clin Oncol. 2020 doi.org/10.1200/JCO.20.00555
  6. Laribi K et al. Bendamustine plus rituximab in newly-diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO). Br J Haematol. 2019; 186(1):146-149. doi:10.1111/bjh.15718
  7. Gertz MA. Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management. Am J Hematol 2023; 98:348-358
  8. Stephens DM, Byrd JC. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia. Blood. 2019; 133(12):1298-1307. doi:10.1182/blood-2018-11-846808
  9. Castillo JJ et al. Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. Blood. 2019;133(4):299-305. doi:10.1182/blood-2018-10-87959
  10. Castillo JJ, Treon SP. Management of  Waldenström macroglobulinemie in 2020. Hematology 2020 - ASH education program

 

Ga terug naar de WM homepage of lees meer over WM:

Ga terug naar de algemene homepage Behandelprotocollen.